Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.

Background: As a prelude to combination studies aimed at resistance reversal, this dose-escalation/dose-expansion study investigated the selective Src kinase inhibitor saracatinib (AZD0530) in combination with carboplatin and/or paclitaxel.

Methods: Patients with advanced solid tumours received saracatinib once-daily oral tablets in combination with either carboplatin AUC 5 every 3 weeks (q3w), paclitaxel 175 mg m(-2) q3w, paclitaxel 80 mg m(-2) every 1 week (q1w), or carboplatin AUC 5 plus paclitaxel 175 mg m(-2) q3w. The primary endpoint was safety/tolerability.

A case-acquisition and decision-support system for the analysis of group-average lactation curves.

A case-acquisition and decision-support system was developed to support the analysis of group-average lactation curves and to acquire example cases from domain specialists. This software was developed through several iterations of a three-step approach involving 1) problem analysis and formulation in consultation with two dairy nutrition specialists; 2) development of a case-acquisition and decision-support prototype by the system developer; and 3) use of the prototype by the domain specialists to analyze and classify milk-recording data from example herds. The overall problem was decomposed into three subproblems: removal of outlier tests and lactation curves of individual cows; interpretation of group-average lactation curves; and diagnosis of detected abnormalities at the herd level through the identification of potential management deficiencies.